The IRE Resource Center is a major research library containing more than 27,000 investigative stories.

Most of our stories are not available for download but can be easily ordered by contacting the Resource Center directly at 573-882-3364 or where a researcher can help you pinpoint what you need.

Search results for "Bristol-Myers" ...

  • The cell game: Sam Waksal's fast money and false promises -- and the fate of ImClone's cancer drug

    This book is a behind-the-scenes look at ImClone and the biotech company's CEO, Sam Waksal. ImClone's drug Erbitux promised a revolutionary way to treat cancer. Bristol-Myers Squibb signed an unprecedented $2 billion deal to market the drug. Waksal lived a life of luxury. But by late December 2001 the FDA rejected Erbitux because ImClone's science was "sloppy" and "incomplete." Waksal tried to cash in before his stock plummeted on the news. He forged signatures and traded his family's shares on inside information, an unfolding scandal that also ensnared Martha Stewart, a friend of Waksal. He is now in jail.
  • Pitch to Switch: Bristol-Myers Fights To Lock In Patients Before Generics Hit

    The Wall Street Journal looks at Bristol-Myers' fight to woo patients to a new diabetes medication that isn't substantially different, but is shielded from generic competition. "If the aggressive marketing campaign succeeds, it could mean that tens of thousands of elderly and poor patients--groups for which diabetes has reached epidemic proportions--will keep using the high-priced alternatives from Bristol-Myers."
  • ImClone Systems

    An investigation by The revealed questions over ImClone Systems handling of its drug Erbitux, long before an early morning raid in June 2002 that ended with the company's CEO, Sam Waksal, handcuffed by police. In late 2001, The reported on a sweetheart loan that went to Waksal during negotiations with Bristol-Myers. It also reported that something was amiss with the Erbitux application two weeks before the Food and Drug Administration rejected the application. Throughout 2002, while others focused on the insider trading scandal involving Waksal and Martha Stewart, The remained focused on ImClone and "the trouble it was having getting Erbitux back on track.
  • Child Play: Pharmaceutical Firms Win Big on Plan to Test Adult Drugs on Kids

    The Wall Street Journal reports on "a drug-industry financial bonanza," resulting from the additional marketing exclusivity that drug makers have won by starting pediatric trials of adult medicine. The story examines the loopholes that allow the pharmaceuticals giants to protect themselves from generic competition half-a-year and earn extra revenues. The reporter reveals that "makers of generic drugs ... could lose $10.7 billion in sales over 20 years as a result of the six-month extension" for the patents of the brand-name drugs. The story looks at a number of flaws in the regulatory process.
  • New Regimen: AIDS-Drug Price War Breaks Out in Africa, Goaded by Generics

    A Wall-Street Journal analysis looks at the AIDS-drug market, and finds that "pharmaceutical giants seek to blunt a growing threat from generic-drug companies and recoup some moral high ground amid the crippling epidemic." The story reports on the slashing of the prices by the biggest drug-makers. It also includes a table of prices for AIDS per patient per year in the U.S. and Africa offered by large drug makers and two Indian generic drug companies.
  • Adverse Reaction: AIDS Gaffes in Africa Come Back to Haunt Drug Industry at Home

    The Wall Street Journal examines the increasing risks to the pharmaceutical companies, if they continue "to conduct their business as usual - by finding and patenting a few new drugs, pricing them high and marketing them aggressively..." The story finds that AIDS-drug price cuts in poor nations have deepened U.S. pharmaceuticals industry domestic trouble, as the firms have revealed the 'true' cost of pills. The article points to evidence that some "medicines are priced - excluding research expenses - at eight to 10 times their cost of manufacturing and distribution. The reporter finds that even though drug makers "poured $80 million into last year's Congressional campaign... their credibility is weakening in the public eye." The story also looks at the possibility for government-mandated price-controls for prescription drugs.
  • (Untitled)

    Fortune (New York) reports on "trade loading" in the consumer-goods industry, the overshipping of products to customers in order to inflate sales and profits; Philip Morris has increasingly relied on trade loading in order to cover up the fact that consumer demand for its brands, particularly Marlboro, is declining; Bristol-Myers Squibb overshipped drugs to prop up 1992 profits.